Skip to main content

Advertisement

SpringerLink
Log in

Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data

  • Original Article
  • Published:
Neurological Sciences Aims and scope Submit manuscript

Abstract

Background

Erenumab is a monoclonal antibody acting against calcitonin gene-related peptide receptor which has been found effective even for the treatment of chronic migraine (CM) complicated with medication overuse headache (MOH). According to the present guidelines, the treatment with erenumab should continue for up to 1 year. The aim of the present study is to explore the evolution of patients affected by CM and MOH at the baseline, after erenumab discontinuation.

Methods

One hundred and eighty-five patients affected by CM and MOH were recruited and followed up after erenumab discontinuation. The number of migraine days per month, the number of painkillers taken per month, the number of days in which one medication was used for a month were collected every 30 days for the 3 months following erenumab suspension.

Results

At the 3rd month after suspension, patients displayed a significantly higher number of migraine days per month, a significantly higher painkiller consumption, and a significantly higher migraine-related disability. A high body mass index and the presence of aura were positively correlated with the relapse of CM and MOH.

Conclusion

Patients affected by CM and MOH at the baseline displayed a significant worsening of their headaches after erenumab discontinuation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

The dataset analyzed during the current study is available from the corresponding author on reasonable request.

Code availability

Not applicable.

Abbreviations

CGRP:

Calcitonin gene-related peptide

CM:

Chronic migraine

ICHD-3:

International Classification of Headache Disorders-3rd Edition

MDM:

Migraine days per month

MIDAS:

Migraine disability assessment questionnaire

MOH:

Medication overuse headache

NDM:

Number of days on medication

NRS:

Numeric rating scale score

PTPM:

Number of painkillers taken per month

References

  1. Ashina M (2020) Migraine. N Eng J Med 383:1866–1876. https://doi.org/10.1056/NEJMra1915327

    Article  CAS  Google Scholar 

  2. Headache Classification Committee of the International Headache Society (IHS) (2018) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 38:1–211. https://doi.org/10.1177/0333102417738202

    Article  Google Scholar 

  3. Diener HC, Holle D, Solbach K, Gaul C (2016) Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol 12:575–583. https://doi.org/10.1038/nrneurol.2016.124

    Article  PubMed  Google Scholar 

  4. GBD (2016) Disease and Injury Incidence and Prevalence Collaborators (2017) Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390:1211–1259. https://doi.org/10.1016/S0140-6736(17)32154-2

    Article  Google Scholar 

  5. Chiang CC, Schwedt TJ, Wang SJ, Dodick DW (2016) Treatment of medication-overuse headache: a systematic review. Cephalalgia 36:371–381. https://doi.org/10.1177/0333102415593088

    Article  PubMed  Google Scholar 

  6. Sun-Edelstein C, Rapoport AM, Rattanawong W, Srikiatkhachorn A (2021) The evolution of medication overuse headache: history, pathophysiology and clinical update. CNS Drugs 35:545–565. https://doi.org/10.1007/s40263-021-00818-9

    Article  PubMed  Google Scholar 

  7. Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, Guerzoni S (2021) Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. Neurol Sci 42:4193–4202. https://doi.org/10.1007/s10072-021-05105-5

    Article  PubMed  Google Scholar 

  8. Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD, Martelletti P (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20:6. https://doi.org/10.1186/s10194-018-0955-y

    Article  PubMed  PubMed Central  Google Scholar 

  9. De Matteis E, Affaitati G, Frattale I, Caponnetto V, Pistoia F, Giamberardino MA, Sacco S, Ornello R (2021) Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci 42:3297–3303. https://doi.org/10.1007/s10072-020-05022-z

    Article  PubMed  Google Scholar 

  10. Gantenbein AR, Agosti R, Gobbi C, Flugel D, Schenkin CJ, Viceic D, Zecca C, Pohl H (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment - a real-life cohort study. Cephalalgia 41:1181–1186. https://doi.org/10.1177/03331024211014616

    Article  PubMed  PubMed Central  Google Scholar 

  11. Raffaelli B, Terhart M, Overeem LH, Mecklenburg J, Neeb L, Steinicke M, Reuter U (2021) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia; 3331024211046617. https://doi.org/10.1177/03331024211046617.

  12. Yang M, Rendas-Baum R, Varon SF, Kosinski M (2011) Validation of the Headache Impact Test (HIT-6TM) across episodic and chronic migraine. Cephalalgia 31:357–367. https://doi.org/10.1177/0333102410379890

    Article  PubMed  PubMed Central  Google Scholar 

  13. D’Amico D, Mosconi P, Genco S, Usai S, Prudenzano AMP, Grazzi L, Leone M, Puca FM, Bussone G (2001) The migraine disability assessment (MIDAS) questionnaire: translation and reliability of the Italian version. Cephalalgia 10:947–952. https://doi.org/10.1046/j.0333-1024.2001.00277.x

    Article  Google Scholar 

  14. Raffaelli B, Mussetto V, Israel H, Neeb L, Reuter U (2019) Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination. J Headache Pain 20:66. https://doi.org/10.1186/s10194-019-1018-8

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. DeMatteis E, Guglielmetti M, Ornello R, Spuntarelli V, Martelletti P, Sacco S (2020) Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother 20:627–641. https://doi.org/10.1080/14737175.2020.1772758

    Article  CAS  Google Scholar 

  16. Lee MJ, Lee SY, Cho S, Kang ES, Chung CS (2018) Feasibility of serum CGRP measurement as a biomarker of chronic migraine: a critical reappraisal. J Headache Pain 19:53. https://doi.org/10.1186/s10194-018-0883-x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Greco R, De Icco R, Demartini C, Zanaboni AM, Tumelero E, Sances G, Allena M, Tassorelli C (2020) Plasma levels of CGRP and espression of specific microRNAs in blood cells of episodic and chronic migraine subjects: towards the identification of a panel of peripheral biomarkers of migraine? J Headache Pain 21:122. https://doi.org/10.1186/s10194-020-01189-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Tringali G, Vollono C, Calabresi P, Navarra P (2020) A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB. J Headache Pain 21:124. https://doi.org/10.1186/s10194-020-01193-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bigal ME, Lipton RB (2011) Migraine chronification. Curr Neur Neurosci Rep 11:139–148. https://doi.org/10.1007/s11910-010-0175-6

    Article  Google Scholar 

  20. Marics B, Peitl B, Varga A, Pàzmàndi K, Bàcsi A, Németh J, Szilvàssy Z, Jancsò G, Dux M (2017) Diet-induced obesity alters dural CGRP release and potentiates TRPA1-mediated trigeminovascular responses. Cephalalgia 37:581–591. https://doi.org/10.1177/0333102416654883

    Article  PubMed  Google Scholar 

  21. Vernieri F, Altamura C, Brunelli N, Maria Costa C, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia C, d’Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22:35. https://doi.org/10.1186/s10194-021-01247-1

    Article  CAS  Google Scholar 

  22. Alpuente A, Gallardo VJ, Torres-Ferrùs M, Alavrez-Sabin J, Pozo-Rosich P (2020) Short and mid-term predictors of response to OnabotulinmtoxinA: real-life experience observational study. Headache 60:677–685

    Article  Google Scholar 

  23. Tozzi A, De Iure A, Di Filippo M, Costa C, Caproni S, Pisani A, Bonsi P, Picconi B, Cupini LM, Materazzi S, Geppetti P, Sarchielli P, Calabresi P (2012) Critical role of calcitonin gene-related peptide receptors in cortical spreading depression. Proc Natl Acad Sci 109:18985–18990

    Article  CAS  Google Scholar 

  24. Close LN, Eftekhari S, Wang M, Charles AC, Russo AF (2019) Cortical spreading depression as a site of origin for migraine: role of CGRP. Cephalalgia 39:428–434

    Article  Google Scholar 

  25. Baraldi C, Ornello R, Favoni V, Sacco S, Caponnetto V, Pierangeli G, Pani L, Cevoli S, Guerzoni S (2021) Chronic migraine and medication overuse headache worsening after OnabotulinumtoxinA withdrawn due to the severe acute respiratory syndrome-coronavirus-2 pandemic. Front Neurol 12:647995

    Article  Google Scholar 

Download references

Acknowledgements

None.

Funding

No funding was received for this work.

Author information

Author notes

  1. Simona Guerzoni and Carlo Baraldi contributed equally to the manuscript and are shared first authors.

Authors and Affiliations

  1. Medical Toxicology-Headache and Drug Abuse Research Center, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

    Simona Guerzoni, Maria Michela Cainazzo & Luca Pani

  2. PhD School in Neuroscience, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

    Carlo Baraldi

  3. Post-Graduate School of Neurology, Department of Biomedical and Neuromotor Sciences of Bologna, University of Bologna, Bologna, Italy

    Umberto Pensato

  4. IRCCS Istituto Delle Scienze Neurologiche Di Bologna, Bologna, Italy

    Valentina Favoni & Sabina Cevoli

  5. Post-Graduate School of Pharmacology and Clinical Toxicology, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

    Flavia Lo Castro

  6. Pharmacology Unit, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy

    Luca Pani

  7. Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, USA

    Luca Pani

  8. VeraSci, Durham, NC, USA

    Luca Pani

Authors
  1. Simona Guerzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carlo Baraldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Umberto Pensato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valentina Favoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Flavia Lo Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maria Michela Cainazzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sabina Cevoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Luca Pani
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

LP, SG, and SC conceived and designed the study. Material preparation and data collection were performed by SG, BC, FLC, MMC, UP, VF, and SC. Data analysis was performed by CB and UP. The first draft of the manuscript was written by CB and reviewed by LP. All authors commented on previous versions of the manuscript. All authors read and approved the final version of the manuscript.

Corresponding author

Correspondence to Carlo Baraldi.

Ethics declarations

Ethical approval

The study was approved by the Area Vasta Emilia Nord Ethics Committee (protocol number: 50/2020/OSS/AOUMO) and by the Area Vasta Emilia Centro (protocol number:). All procedures were conducted in accordance with the latest version of the declaration of Helsinki.

Informed consent

Every subject signed an informed consent to participate in the study and for data publication.

Conflict of interest

CB received travel grants and honoraria from Allergan, Teva, Novartis, and Ely Lilly. VF received honoraria as a speaker or for participating in advisory boards from Ely Lilly, Novartis, and Teva. MMC received travel grants and honorary from Allergen, Novartis, Ibsa, and Ely Lilly. SC received travel grants, honoraria for advisory boards, speaker panels, or clinical investigation studies from Novartis, Teva, Lilly, Allergan, Ibsa, and Lundbeck. SG received travel grants and honoraria from Allergan, Teva, Novartis, and Ely Lilly. LP is the Chief Scientific Officer of EDRA-LSWR Publishing Company and of Inpeco SA Total Lab Automation Company. In the last year he has been a scientific consultant to AbbVie, USA; BCG, Switzerland; Boehringer-Ingelheim, Germany; Compass Pathways, UK; Johnson & Johnson, USA; Takeda, USA; VeraSci, USA; Vifor, Switzerland. FLC and UP declare they have no conflict of interests to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guerzoni, S., Baraldi, C., Pensato, U. et al. Chronic migraine evolution after 3 months from erenumab suspension: real-world-evidence-life data. Neurol Sci 43, 3823–3830 (2022). https://doi.org/10.1007/s10072-022-05870-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10072-022-05870-x

Keywords

Search

Navigation